FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385554134> ?p ?o ?g. }

• W4385554134 endingPage "57" @default.
• W4385554134 startingPage "57" @default.
• W4385554134 abstract "57 Background: Gastric carcinomas (GC) can be divided into immunogenic and immune-resistant based on the infiltration of the tumour microenvironment (TME) from different immune cells (ICs) such as Natural Killer (NK), activated CD8+, CD3+ and CD4+ memory T cells. High ImmunoScore (IS) (positive cells/mm2 for each marker (CD8+, CD3+, Foxp3+) in the Core Tumour and Invasive Margins) is strongly related to better prognosis of GC patients in terms of Disease-Free Survival and Overall Survival. ICs activation and consequent immunogenic TME requires high nutrient absorption and synthesis accumulation of protein, lipid and nucleotides. However, tumour cells (TCs) promote their own proliferation by stealing the available micronutrients to ICs therefore leading to an immunosuppressive TME phenotype. Methods: This is a translational, prospective, non-randomized study. Primary endpoint is to assess if enteral immune nutrition (EIN) supplementation during the acme of the activity of cytotoxic of perioperative FLOT (docetaxel, oxaliplatin and 5-fluorouracil) in stage II-III GC can revert the TME in favour of ICs over TCs, witnessed by an increase of IS in surgical specimen over biopsy controls. A steady amount of EIN with Arginine, Omega-3-fatty acids, Glutamine and ribonucleic acid, will be added to patient’s diet from day 3 to 8 of each FLOT cycle, twice a day. We plan to use Image analysis software for automatic tumor detection and quantification of CD3+ and CD8+ stained cells whose densities will be converted into IS with pre-defined cutoffs. IS utilizes standardized percentile values (0 to 100%). We identify IS as Low, Intermediate (Int) and High with a mean percentile of 0-25%, >25-70%, >70-100% respectively. Two-group classifications are planned, corresponding to IS Low and Int-High. To better define the kind of tumor infiltrating cells (TILs) and assess the amount of immune suppressive cells, more IHC scoring will be evaluated: helper T-cells CD4+, CD8 T memory (CD 103+), T regulatory (both CD4+ and Foxp3+/CD105+), Macrophages M1 (CD 68+) and M2 (CD 163+). Results: Based on historical controls the rate of Int-High IS (>25-70%, >70% respectively) is about 64%, we expect to find a 20% increase of Int-High IS GC over biopsy control (internal validation cohort). To detect an increase in the percentage of high IS among patients treated with EIN (estimated around 85%) compared to biopsy controls (estimated around 64%) assuming a probability α and β of 0.2, the required sample size will be of 21 patients with resectable GC receiving EIN supplementation plus standard CT. To define the sample size a single proportion test was used. Conclusions: Our hypothesis is that EIN given during perioperative CT might prevent the establishment of an unfavourable TME for ICs in both auxotrophic and non-auxotrophic malignancies, thus leading to an increase of GC immunogenic pattern." @default.
• W4385554134 created "2023-08-04" @default.
• W4385554134 creator A5003848263 @default.
• W4385554134 creator A5007635105 @default.
• W4385554134 creator A5009107823 @default.
• W4385554134 creator A5012233597 @default.
• W4385554134 creator A5016471155 @default.
• W4385554134 creator A5019178527 @default.
• W4385554134 creator A5034035272 @default.
• W4385554134 creator A5037658807 @default.
• W4385554134 creator A5048129292 @default.
• W4385554134 creator A5053115235 @default.
• W4385554134 creator A5063263109 @default.
• W4385554134 creator A5072853471 @default.
• W4385554134 creator A5076563915 @default.
• W4385554134 creator A5080291428 @default.
• W4385554134 creator A5084397197 @default.
• W4385554134 creator A5092084961 @default.
• W4385554134 creator A5092593166 @default.
• W4385554134 date "2023-08-01" @default.
• W4385554134 modified "2023-09-26" @default.
• W4385554134 title "Immunonutrition supplementation for resectable gastric cancer during standard perioperative chemotherapy (CT) FLOT: A pivotal study, I–SUPPLY." @default.
• W4385554134 doi "https://doi.org/10.1200/go.2023.9.supplement_1.57" @default.
• W4385554134 hasPublicationYear "2023" @default.
• W4385554134 type Work @default.
• W4385554134 citedByCount "0" @default.
• W4385554134 crossrefType "journal-article" @default.
• W4385554134 hasAuthorship W4385554134A5003848263 @default.
• W4385554134 hasAuthorship W4385554134A5007635105 @default.
• W4385554134 hasAuthorship W4385554134A5009107823 @default.
• W4385554134 hasAuthorship W4385554134A5012233597 @default.
• W4385554134 hasAuthorship W4385554134A5016471155 @default.
• W4385554134 hasAuthorship W4385554134A5019178527 @default.
• W4385554134 hasAuthorship W4385554134A5034035272 @default.
• W4385554134 hasAuthorship W4385554134A5037658807 @default.
• W4385554134 hasAuthorship W4385554134A5048129292 @default.
• W4385554134 hasAuthorship W4385554134A5053115235 @default.
• W4385554134 hasAuthorship W4385554134A5063263109 @default.
• W4385554134 hasAuthorship W4385554134A5072853471 @default.
• W4385554134 hasAuthorship W4385554134A5076563915 @default.
• W4385554134 hasAuthorship W4385554134A5080291428 @default.
• W4385554134 hasAuthorship W4385554134A5084397197 @default.
• W4385554134 hasAuthorship W4385554134A5092084961 @default.
• W4385554134 hasAuthorship W4385554134A5092593166 @default.
• W4385554134 hasBestOaLocation W43855541341 @default.
• W4385554134 hasConcept C121608353 @default.
• W4385554134 hasConcept C126322002 @default.
• W4385554134 hasConcept C141071460 @default.
• W4385554134 hasConcept C143998085 @default.
• W4385554134 hasConcept C167672396 @default.
• W4385554134 hasConcept C203014093 @default.
• W4385554134 hasConcept C2776107976 @default.
• W4385554134 hasConcept C2780962732 @default.
• W4385554134 hasConcept C31174226 @default.
• W4385554134 hasConcept C502942594 @default.
• W4385554134 hasConcept C526805850 @default.
• W4385554134 hasConcept C71924100 @default.
• W4385554134 hasConcept C8891405 @default.
• W4385554134 hasConceptScore W4385554134C121608353 @default.
• W4385554134 hasConceptScore W4385554134C126322002 @default.
• W4385554134 hasConceptScore W4385554134C141071460 @default.
• W4385554134 hasConceptScore W4385554134C143998085 @default.
• W4385554134 hasConceptScore W4385554134C167672396 @default.
• W4385554134 hasConceptScore W4385554134C203014093 @default.
• W4385554134 hasConceptScore W4385554134C2776107976 @default.
• W4385554134 hasConceptScore W4385554134C2780962732 @default.
• W4385554134 hasConceptScore W4385554134C31174226 @default.
• W4385554134 hasConceptScore W4385554134C502942594 @default.
• W4385554134 hasConceptScore W4385554134C526805850 @default.
• W4385554134 hasConceptScore W4385554134C71924100 @default.
• W4385554134 hasConceptScore W4385554134C8891405 @default.
• W4385554134 hasIssue "Supplement_1" @default.
• W4385554134 hasLocation W43855541341 @default.
• W4385554134 hasOpenAccess W4385554134 @default.
• W4385554134 hasPrimaryLocation W43855541341 @default.
• W4385554134 hasRelatedWork W2352247659 @default.
• W4385554134 hasRelatedWork W2354785620 @default.
• W4385554134 hasRelatedWork W2375359181 @default.
• W4385554134 hasRelatedWork W2393177352 @default.
• W4385554134 hasRelatedWork W2586998360 @default.
• W4385554134 hasRelatedWork W2767618185 @default.
• W4385554134 hasRelatedWork W2771066073 @default.
• W4385554134 hasRelatedWork W3197243161 @default.
• W4385554134 hasRelatedWork W4319770546 @default.
• W4385554134 hasRelatedWork W4324096639 @default.
• W4385554134 hasVolume "9" @default.
• W4385554134 isParatext "false" @default.
• W4385554134 isRetracted "false" @default.
• W4385554134 workType "article" @default.